Modern Rheumatology is a premier journal dedicated to advancing the field of rheumatology through high-quality peer-reviewed research. Published by Oxford University Press, this journal reflects the latest developments in rheumatologic medicine, catering to researchers, clinicians, and students alike. With an H-Index highlighting its scholarly impact, Modern Rheumatology occupies a notable position, ranking Q2 in both the fields of Medicine and Rheumatology in 2023, and is listed among the top 25 journals in its category by Scopus. Spanning from the year 2000 to 2024, the journal features a diverse array of topics aimed at addressing current challenges and innovations in the field. Although it does not offer Open Access, it provides essential insights for professionals seeking to stay abreast of evolving treatment modalities and research breakthroughs. Located in the heart of the United Kingdom, Modern Rheumatology is a vital resource for anyone committed to enhancing the understanding and treatment of rheumatic diseases.

Current Rheumatology Reviews is an esteemed journal dedicated to publishing comprehensive reviews on advancements in the field of rheumatology. Established by Bentham Science Publishers, this journal has become a vital resource for researchers, clinicians, and students seeking to stay abreast of the latest developments and therapeutic strategies from 2006 to 2024. Located in the United Arab Emirates, it caters to a global audience, delivering insights that have been pivotal in shaping clinical practices. With an impact factor reflective of its Q3 status in Rheumatology by 2023, the journal ranks #46 out of 73 in the Scopus database, positioning it in the 37th percentile in the discipline. Although it operates without open access, its high-quality content ensures that each article undergoes rigorous peer review, making the Current Rheumatology Reviews a trusted platform for disseminating critical research findings and reviews that drive forward the understanding and treatment of rheumatic diseases.

Dermatology and Therapy is a prestigious Open Access journal, published by ADIS INT LTD since 2011, that has quickly established itself as a vital resource in the field of dermatology. With an impressive Q1 ranking in the Dermatology category as of 2023 and a commitment to disseminating high-quality research, this journal fosters innovation and knowledge exchange among professionals, researchers, and students alike. Its broad scope encompasses the latest advancements in dermatological therapies, contributing significantly to both clinical practice and academic research. Based in Germany and operating under a global perspective, Dermatology and Therapy provides an essential platform for open access research, encouraging unrestricted access to groundbreaking studies and fostering collaboration across borders. Join the community of dermatology experts by exploring the wealth of knowledge available in this influential journal.

The Lancet Neurology is a premier academic journal published by Elsevier Science Inc, specializing in the field of neurology. With a robust impact factor that signifies its authoritative presence, it consistently ranks in the Q1 category for clinical neurology according to the 2023 standards, positioning itself as the leading journal in its domain, ranking #1 out of 400 in Scopus' neurology rankings and placing in the 99th percentile. Since its establishment in 2002, it has provided a vital platform for disseminating innovative research and clinical advances related to neurological disorders. The journal’s precise focus includes cutting-edge studies on neurodegenerative diseases, stroke, epilepsy, and neuroimaging, which are essential for advancing clinical practice and improving patient outcomes. While it does not offer open access, readers can find high-impact research published monthly, making it indispensable for practitioners, researchers, and students eager to stay at the forefront of neurological science.

The Scandinavian Journal of Rheumatology, published by Taylor & Francis Ltd, is a prestigious peer-reviewed journal dedicated to advancing research in the fields of rheumatology, immunology, and related disciplines. With an ISSN of 0300-9742 and an E-ISSN of 1502-7732, this journal has established itself as a vital platform for disseminating significant findings and innovative approaches in the management of rheumatic diseases since its inception in 1959. As a recognized scholarly outlet, it currently resides within the Q2 category for Medicine (miscellaneous) and ranks #39 out of 73 in Rheumatology according to the 2023 Scopus assessments. This reflects the journal's commitment to high-quality research and its relevance in the scientific community. Although it does not provide Open Access options, the journal's rigorous selection process ensures that only the most impactful research reaches its audience, making it a crucial resource for researchers, clinicians, and students engaged in the exploration of rheumatological and immunological challenges. The journal's broad scope encompasses ongoing studies, clinical trials, and reviews that aim to enhance understanding and treatment of rheumatic conditions, promoting collaboration and knowledge-sharing among professionals in the field.

Multiple Sclerosis International is a leading open-access journal dedicated to advancing the scientific understanding of multiple sclerosis (MS) and related neurological disorders. Published by HINDAWI LTD since 2010, this journal serves as a vital resource for researchers, clinicians, and students alike, providing a platform for high-quality peer-reviewed articles that cover a diverse range of topics, including epidemiology, treatment strategies, and the latest advancements in MS research. With its commitment to open access, Multiple Sclerosis International ensures that critical findings are readily available to the global community, fostering collaborative efforts to improve patient outcomes and advance therapeutic approaches. The journal not only enhances scholarly discourse in the field but also significantly impacts clinical practices by presenting cutting-edge research and insights.

Multiple Sclerosis Journal-Experimental Translational and Clinical, published by SAGE Publications, Inc., is an essential open-access platform since 2015 dedicated to advancing research in the field of multiple sclerosis and related neurological disorders. With an ISSN of N/A and an E-ISSN of 2055-2173, the journal aims to bridge the gap between experimental studies and clinical applications, offering valuable insights into cellular and molecular neuroscience as well as clinical neurology. The journal holds a reputable Q3 ranking in Cellular and Molecular Neuroscience and a Q2 ranking in Neurology (Clinical) for 2023, indicating its significant contribution to these fields. Positioned at the intersection of scientific discovery and clinical practice, the Multiple Sclerosis Journal serves as an indispensable resource for researchers, clinicians, and students dedicated to improving outcomes for individuals affected by multiple sclerosis and related disorders. With a Scopus ranking of #163/400 in Medicine - Neurology and #67/97 in Neuroscience, this journal continues to play a pivotal role in shaping the future of neurological research and therapy.

ANAIS BRASILEIROS DE DERMATOLOGIA is a prestigious academic journal published by Elsevier Science Inc, specializing in the dynamic field of dermatology. With its Open Access model established in 2002, this journal ensures wide dissemination of research findings and facilitates collaboration within the dermatological community. Hailing from Brazil, it provides a platform for innovative research from both local and international contributors, spanning from its inception in 1963 to the current year, 2024. The journal positions itself as a vital resource in the dermatology sphere, currently ranked in the Q3 category for dermatology and holding a notable rank of 71 out of 142 in the Scopus rankings, placing it in the 50th percentile for its field. With a commitment to advancing knowledge and practice in dermatology, ANAIS BRASILEIROS DE DERMATOLOGIA is an essential read for researchers, professionals, and students eager to explore contemporary advancements and clinical practices.

Rheumatology International, published by Springer Heidelberg, is a prestigious journal that focuses on innovative research in the field of rheumatology and immunology. Established in 1981, this peer-reviewed journal has contributed significantly to advancing our understanding of autoimmune disorders, clinical approaches, and therapeutic interventions. It holds a commendable Q2 ranking in the categories of Immunology, Immunology and Allergy, and Rheumatology as of 2023, showcasing its influence and importance within these disciplines. With a robust Scopus ranking—positioned 14 out of 73 in Medicine Rheumatology—it caters to a diverse audience of researchers, clinicians, and students committed to improving patient care and treatment modalities. Although it does not currently offer open access options, the journal remains a vital resource for insights on contemporary challenges and breakthroughs in rheumatological research, published from its base in Heidelberg, Germany.

LUPUS is a premier peer-reviewed journal published by SAGE Publications Ltd, focusing on the field of rheumatology, with a specific emphasis on the complexities of lupus and related autoimmune disorders. Since its inception in 1991, the journal has consistently ranked in the Q2 category within the rheumatology field, currently positioned as #29 out of 73 in Scopus, reflecting its significant contributions to research and clinical practice. The journal aims to foster a deeper understanding of lupus through the publication of original research articles, reviews, and clinical studies, making it an essential resource for researchers, clinicians, and students dedicated to advancing knowledge in this vital area of medicine. With an impact factor that underscores its influence, LUPUS serves as a critical platform for sharing innovative findings and engaging discussions within the global scientific community. Although the journal follows a traditional access model, it is situated in the United Kingdom, at 1 Olivers Yard, 55 City Road, London EC1Y 1SP, England, and remains dedicated to supporting the continuous advancement of research in autoimmune diseases.